更新版儿童IgA肾病预测工具在活检后1–2年的应用
该研究基于947例国际多族裔儿童IgA肾病队列(38%随访至成年),将儿童IgA肾病预测工具更新为活检后1年使用版本。与原始版本相比,更新版模型拟合更优(R2D 51%/50% vs 20%),4年C统计量显著提高(0.83 vs 0.73/0.69),校准更佳;活检后2年应用结果相似。
要点
- 原始儿童IgA肾病预测工具应在活检时使用。
- 更新版预测工具应在活检后1或2年重新评估风险。
- 更新版模型在活检后1年预测4年eGFR下降或肾衰竭的区分度和校准度均优于原始版。
核心结论
- 原始儿童IgA肾病预测工具适用于活检时,更新版预测工具适用于活检后1或2年重新评估风险。
研究设计与样本
- 国际多族裔儿童IgA肾病队列,共947例,38%随访至成年,更新活检后1年预测模型。
主要发现
- 更新版活检后预测工具较原始版模型拟合更优,R2D为51%/50% vs 20%。
- 4年C统计量从0.73/0.69提高至0.83,ΔC分别为0.09(95%CI 0.07–0.10)和0.14(95%CI 0.12–0.15)。
- 4年校准更佳,整合校准指数为0.74/0.54 vs 2.45/1.01。
- 内部验证及活检后2年应用模型时结果相似。
- 基线活检后1年eGFR轨迹呈非线性,高风险组起始eGFR更低且下降更快。
关键数值与推荐
- 儿童eGFR至15–18岁前增长率可变,之后线性下降,高风险组下降速度与同等风险年轻成人相似。
临床怎么用
- 活检时使用原始儿童预测工具评估风险。
- 活检后1或2年使用更新版预测工具重新评估风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The pediatric International IgA Nephropathy (IgAN) Prediction Tool comprises two models with and without ethnicity and is the first method to predict the risk of a 30% decline in estimated glomerular filtration rate (eGFR) or kidney failure in children at the time of biopsy using clinical risk factors and Oxford MEST histology scores. However, it is unknown if the Prediction Tool can be applied after a period of observation post-biopsy. Using an international multi-ethnic cohort of 947 children with IgAN, 38% of whom were followed into adulthood, the Prediction Tool was updated for use one year after biopsy. Compared to the original pediatric Prediction Tool, the updated post-biopsy Prediction Tool had a better model fit with higher R2D (51%/50% vs 20%), significant increase in 4-year C-statistics (0.83 vs 0.73/0.69, ΔC 0.09 [95% confidence interval 0.07-0.10] and ΔC 0.14 [0.12-0.15]) and better 4-year calibration with lower integrated calibration indices (0.74/0.54 vs 2.45/1.01). Results were similar after internal validation and when the models were applied two years after biopsy. Trajectories of eGFR after a baseline one year post-biopsy were non-linear and those at higher predicted risk started with a lower eGFR and experienced a more rapid decline over time. In children, eGFR had a variable rate of increase until 15-18 years old and then decreased linearly with a more rapid decline in higher risk groups that was similar to young adults of comparable risk. Thus, the original pediatric Prediction Tool should be used in children at the time of biopsy, and the updated pediatric Prediction Tool should be used to re-evaluate risk one or two years after biopsy.
引用
- Barbour SJ, Coppo R, Er L, et al. Application of the updated International IgA Nephropathy Prediction Tool in children one or two years post-biopsy. Kidney Int. 2024. PMID: 39094695. doi:10.1016/j.kint.2024.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。